Enhanced Group Brings Athlete-Tested Personalized Protocol-Making to Consumers With Launch of Enhanced OS, Expanding Its Offering Beyond Individual Products

AI platform trained on protocol work from Enhanced’s athlete clinical study combines diagnostics, medical records, wearables and individual goals for personalized protocol recommendations; invitation-based access opens today ahead of planned full launch in January 2027

NEW YORK--(BUSINESS WIRE)--Enhanced Group Inc. (NYSE: ENHA) (“Enhanced” or the “Company”), the elite sports competition and performance products company, today announced the launch of Enhanced OS, an AI-powered platform that brings to consumers the personalized protocol-making the Company developed with elite athletes. Consumers can sign up for early access to Enhanced OS beginning today through https://app.enhanced.com/access. The Company plans a full public launch in January 2027.

Enhanced currently offers 18 prescription products on its homepage across metabolic regulation, hormone optimization, cognitive enhancement and peptides. Consumers can review the products, learn about each, and begin a medical evaluation to determine eligibility. Enhanced OS takes this one step further.

How Enhanced OS Works

Enhanced OS starts with the individual rather than the product. Through an initial intake, the platform captures each person’s specific goals. A 25-year-old training for a marathon and a 45-year-old who wants enough energy after a ten-hour workday to be present with their kids have different objectives, and those objectives may change over time. Enhanced OS combines these personal goals with offering diagnostics, electronic medical records and wearable data to generate a tailor-made protocol recommendation. As wearables sync and diagnostics are repeated, the platform generates proactive recommendations for protocol changes, so that recommendations keep pace with the individual.

Enhanced developed this approach with athletes. In the clinical study Enhanced conducted with athletes ahead of the Enhanced Games, the Company made hundreds of individual protocol adjustments, approximately one per athlete per week. That work generated a body of medical intellectual property on how to design personalized protocols, which now trains the Enhanced OS algorithm. Training the Company’s own AI on this data is expected to improve the quality, consistency and scale of its operations. Every prescription protocol will continue to be reviewed by a licensed clinician, who decides together with the consumer whether it is the right protocol.

Enhanced OS launches with supplement protocols. Prescription integration is planned for the full launch in January 2027.

“Formula One teams build cars at the forefront of science and technology, and what they learn doesn’t stay on the track. Innovations like paddle shifters started in racing and reached the road car later,” said Maximilian Martin, Co-Founder and CEO of Enhanced. “Megan Romano, at 34, beat her 21-year-old self. The protocol behind that is far too complex for the average person. But the work we did with Megan and every athlete taught us how to design personalized protocols, and that is now what trains our AI to build them for consumers.”

Advanced Diagnostics and Biomarker Testing

Enhanced OS includes diagnostics covering more than 100 biomarkers, beginning with one blood test per year, expanding to two per year, with additional testing available on request. The platform can pull electronic medical records, and consumers can upload previous testing and other health information. Wearable integration and real-time insights are included. Together, these inputs give Enhanced OS the most complete picture possible of an individual’s current health. The more data available on a consumer, the better the protocol recommendations.

Personalized Health and Longevity Strategies

Recommendations span supplements and, with the full launch, prescription products, as well as nutrition and exercise recommendations. Protocols are staged across 30-, 60- and 100-day phases, with insights into potential improvements in the consumers health.

“The protocol I’m on today is different from the one six months ago, which is different from the one I was on two years ago. The common denominator is that I’m always enhanced,” Martin added. “When I’m 65, I likely will not take the exact same drugs and protocol that I take today. But I know for sure there will be certain substances that help me be a better version of myself, and I’m always going to be enhanced.”

Access Enhanced OS

Early access to Enhanced OS is invite-only, open to investors and a select group of loyal Enhanced customers. It focuses on the foundation of personal health: diagnostics, connected medical records, wearable integration, biomarker intelligence, supplement protocols and other actionable insights. Full launch is planned for January 2027.

Investors and consumers can join the waitlist today at https://app.enhanced.com/access. Everyone who signs up will be considered for early access, and those who are eligible will be invited as availability opens up.

About Enhanced Group, Inc.

Enhanced (NYSE: ENHA) is an elite sports competition and performance products company committed to giving athletes and consumers access to products that optimize health, performance, and recovery. Its Live Enhanced platform provides consumers with clinician-guided protocols, supplements, and personalized health and longevity offerings. For more information, visit www.enhanced.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated launch, development, features, functionality, and future expansion of Enhanced OS, including diagnostics, electronic medical record integration, wearable integration, and AI-generated protocol recommendations; the planned integration of prescription products into the platform at full launch; and the expected benefits of training Enhanced’s AI on data from its athlete clinical study . These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include development timelines, regulatory requirements, operational considerations, and other factors described in Enhanced Group, Inc.'s filings with the U.S. Securities and Exchange Commission. Enhanced undertakes no obligation to update these statements except as required by applicable law.